Spero Therapeutics Inc CEO Sath Shukla Sells 75,994 Shares
Sath Shukla, CEO and President of Spero Therapeutics Inc (NASDAQ:SPRO), sold 75,994 shares of the company on February 5, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $1.42 per share, resulting in a total value of $107,911.08.
Spero Therapeutics Inc is a biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for multi-drug resistant bacterial infections.
Over the past year, the insider has sold a total of 82,011 shares and has not made any purchases of the company's stock.
The insider transaction history for Spero Therapeutics Inc shows a pattern of selling activity, with 0 insider buys and 10 insider sells over the past year.
On the day of the insider's recent sale, shares of Spero Therapeutics Inc were trading at $1.42, giving the company a market cap of $77.326 million.
The stock's price-earnings ratio stands at 144.00, which is above both the industry median of 27.01 and the company's historical median price-earnings ratio.
With the current share price of $1.42 and a GuruFocus Value of $3.35, Spero Therapeutics Inc has a price-to-GF-Value ratio of 0.42, indicating that the stock may be a possible value trap and warrants caution before investing.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
